trending Market Intelligence /marketintelligence/en/news-insights/trending/Mo1ogW3hsIkD9zei_2wstA2 content esgSubNav
In This List

ATAI Life buys majority stake in Perception Neuroscience alongside PE firms

Podcast

Street Talk | Episode 98: Regulatory scrutiny having cooling effect on community bank M&A

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Podcast

Street Talk | Episode 97: Recessionary fears still keeping bank investors on the sidelines


ATAI Life buys majority stake in Perception Neuroscience alongside PE firms

Private equity firm Morgan Noble Healthcare Partners, venture capital firm Subversive Capital LLC and life-sciences investor WPSS Investments co-invested alongside biotechnology company ATAI Life Sciences AG to acquire a majority stake in biopharmaceutical company Perception Neuroscience for an undisclosed amount.

Perception founders Jonathan Sporn and Jay Kranzler will retain minority stakes in the company, which is developing a ketamine-based rapid-acting antidepressant drug. ATAI said the arketamine drug is expected to be more effective than current FDA-approved antidepressants, which can take weeks to become effective.

Morgan Noble invests in transformative healthcare treatments, and Subversive Capital works with companies requiring sophisticated government and regulatory assistance.

PJT Partners advised on the transaction.